This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Worst IPO Peddling Isn't Social Media

NEW YORK ( TheStreet) -- The social media space isn't the only IPO game in town where prospectuses may be a lot rosier than actual company prospects.

In fact, the worst sector recently foisted on the investing public by the IPO underwriters has nothing to do with the Internet. It's rather companies in the biofuels and bioproducts arena that have been the real IPO sucker's bet.

On Friday, Amyris (AMRS - Get Report), taken public in an offering led by Goldman Sachs (GS - Get Report) and Morgan Stanley (MS - Get Report), pulled its 2012 guidance and said it would need to raise a dilutive round of private financing to shore up the balance sheet.

Amyris shares promptly tanked nearly 30%, bringing the company's all-time return since its IPO to negative 60%. The company priced at $16 in 2010 and now is trading under $7.

Solazyme (SZYM - Get Report) -- also taken public by Goldman and Morgan, is down 45% since its IPO in May of last year. The stock priced at $18 and is now trading near $11.50.

And the roll of bad biofuels IPOs continues.

KiOR (KIOR) -- taken public by Goldman, Credit Suisse (CS) and UBS (UBS) -- is now down 16% since its IPO last summer, which priced at $15. Shares are now trading at $12.30.

Gevo (GEVO - Get Report) -- taken public by Goldman and UBS and now down 50% all-time -- priced its IPO at $15 in early 2011, and is now trading at $8.50.

In fact, there isn't one recent biofuels IPO that is trading above its IPO price today. And it's not as if these stocks have been beholden to a weak market dragging them lower: all of the major indexes are at least in the green over the last one year period. Even as the risk-on equities trade early this year led the S&P 500 up by more than 7% and the Nasdaq Composite up 11%, biofuels shares continue to head in the other direction.

Codexis (CDXS - Get Report), taken public by Credit Suisse at $13, now trades under $5.

Metabolix (MBLX), taken public by Piper Jaffray at $14, now trades under $3. Metabolix is the oldest of the bunch, going public way back in 2006, and even five years after its IPO -- plenty of time to prove that those lean, profit-less early years would ultimately pay dividends -- the company's situation has only worsened.

Its major corporate backer, Archer Daniels Midland (ADM), recently pulled out of its investment in a Metabolix major project, leading shares to their latest crash in January.

Don't think the biofuels parade will stop, though. Goldman has plans to take Ceres public, though the biofuel feedstock company recently lowered its price range and delayed an offering that had been scheduled for this week.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
KIOR $0.01 -3.45%
AMRS $2.13 0.00%
CDXS $3.52 0.00%
GS $180.32 0.00%
GEVO $2.06 0.00%


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs